Next Phase Newsletter

A family-run investment and commercialization vehicle invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs.

The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also considered attractive.

The firm has a strong preference for experienced management teams with proven tracks records of driving value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a USD 100 million fund. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Canada is making investments out of its vintage 2017, fourth fund and is exclusively focused on supporting entrepreneurs commercializing advanced materials and advanced material process innovations within four verticals: energy, electronics, health, and sustainability. The firm typically makes initial investments in the $1M-$4M range and up to $8M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. The firm has strategic LP relationships in Asia, Europe, the Middle East, and North America and invests globally.

Within healthcare, the firm is interested in medical devices and diagnostics whose underlying technology is enabled by advanced materials or advanced material process innovations. The firm has a particular interest in 3D bioprinting, diagnostics and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing a disruptive 3D bioprinting platform, and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm specializing in technologies, financials and healthcare industries has an investment management team that includes many experts and experienced professionals from hospitals and healthcare systems.  The firm has partnered with premier hospitals in the US, Taiwan and China to introduce new technologies.

The investment strategy of the firm has three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with their domestic and foreign hospital & medical network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The healthcare and life sciences branch of a global technology corporation and manufacturing company looks to invest primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic to the parent company, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. Firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm based in Japan makes venture stage investments, with  a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, centered on Japan and Taiwan. However, the firm may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine. The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area. The firm invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor. For early stage opportunities, the firm prefers that the company has a clinical trial plan in place. While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.